# Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

> **NCT06801834** · PHASE3 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 695 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **DRUG:** Sacituzumab Govitecan (SG)
- **DRUG:** Topotecan
- **DRUG:** Amrubicin (Japan only)
- **DRUG:** Lurbinectedin (regions/countries where approved and available)

## Key facts

- **NCT ID:** NCT06801834
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-04
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 695 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801834, "Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06801834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*